Chock-a-block first session at BOA India at Chandigarh.   "PUNJAB MEDICAL COUNCIL" to Best of ASCO 2017, 14-16th July 2017, Chandigarh, Punjab.   Best of ASCO INDIA 2017 Conference to be held at Chandigarh from 14 th to 16 th July 2017 For more information contact Dr. Gautam Goyal email: bestofascoindia2017@yahoo.com , goyal_gautam@yahoo.com , Dr Purvish Parikh email: purvish1@gmail.com  
Best of ASCO 2017, 14th-16th July 2017,Chandigarh
Scientific Program 14th July 2017, Friday (Day 1)
Time Hall Topic
12.00 onwards     Registration
16.30-19.30   Hall 1  GI Session- Director - J S Sekhon
Time Chairperson  D C Doval,Mohan Das,Harit Chaturvedi, Rajesh Vashishtha
16.30-16.37   Atul Batra  Primary (1°) tumor location is an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance).
16.38-16.45  Jatin Sarin  Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406)
16.46-16.53  Chetan Deshmukh   American Cancer Society (ACS) Nutrition and Physical Activity Guidelines after colon cancer diagnosis and disease-free (DFS), recurrencefree (RFS), and overall survival (OS) in CALGB 89803 (Alliance).
     Panel Discussion
16.55-17.25  Moderator  T.Raja
  Panelist  Chirag Desai,Sachin Jain,Mukul Goyal,Vikas Goyal,Sumit Goyal,Kumardeep Dutta,Munita Bal,Vinod Nimbran
17.30-17.37  Nikhil Ghadyalpatil  Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).
17.38-17.45  Tejinder Singh  Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study
17.46-17.53  Padmaj Kulkarni  Results of the randomized phase II portion of NRG Oncology/RTOG 0848 evaluating the addition of erlotinib to adjuvant gemcitabine for patients with resected pancreatic head adenocarcinoma.
     Panel Discussion
17.55-18.25  Moderator  B K Smruti 
  Panelist   Linu Jacob,Avinash Pandey,Smita Gupte,S P Kataria,Arun Kumar Goel,Meenakshi Mittal,Somnath Sorcer,Prashant Parida
18.30-18.37  Pranav Chhadda  Overall survival analysis of the FOXFIRE prospective randomized studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer.
18.38-18.45  Vamshi Krishna  Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.
18.46-18.53   Bharat Bhosale  Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study.
     Panel Discussion
18.55-19.25  Moderator  G S Bhattacharaya
  Panelist  Avinash Saklani,Kapil Kumar,Rakesh Kapoor,Anil Heroor,Sumit Jain,Pamella Jeyaraj,Neeraj Rastogi,Gaurav Kaushal,Muzammil Shaikh,Jatin Sarin
19.30-20.00     Sponsored Session(Lilly)
  Chairpersons  D C Doval 
  Senthil Rajappa  THE RAINBOW IN GASTRIC CANCER
  T Raja  Making the RAINBOW VIVID
  Panelist  Maheboob Basade,Senthil Rajappa,B K Smruti,Nikhil Ghadyalpatil
20.15-21.00     Sponsored Session(Dr. Reddys)
  Chairpersons  D C Doval,Maheboob Basade
  T. Raja  Right Choice for left sided metastatic Colorectal Cancer-Current Evidence
  Senthil Rajappa  Sequencing of anti-VEGF and anti-EGFR mAbs in the management of mCRC
  Panelist  T P Sahoo,Sachin Gupta,Jatin Sarin,K V Gangadharan,Chetan Deshmukh,P K Das
17.30-19.30   Hall 2  Gynecological Session- Director - Amita Maheshwari
  Chairperson   Veena Jain,Raman Arora,Lakshmaiah K C
17.30-17.37  Pankaj Kumar   Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer.
17.38-17.45  Shailesh Bondarde   A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma.
     Panel Discussion
17.50-18.20  Moderator   Shona Nag
  Panelist  Sudeep Gupta,Amit Bhargava,Krishna Mohan,Satinder Kaur,Amit Oza,Kinsley Dimri,Vijayanand Reddy,Manoj Parashar
18.25-18.32   Rahul Roy Choudhary  Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer.
18.33-18.40  Kunal Jain   Effect of health-related quality of life (HRQOL) and patient-centered outcomes on the clinical benefit of prolongation of progression-free survival (PFS) with olaparib maintenance following chemotherapy in patients with germline (g) BRCA-mutated (m) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): SOLO2 phase III trial.
18.41-18.48  Shyalshree   LION: Lymphadenectomy in ovarian neoplasms—A prospective randomized AGO study group led gynecologic cancer intergroup trial.
     Panel Discussion
18.50-19.20  Moderator   TP Sahoo
  Panelist   Ajay gupta,Tanveer Maqsood,Aseem samar,Amitabh Upadhayay,B K Mishra,Joydeep Ghosh,Shaveta Gupta,Sampada Desai,Manoj Gupta,Somashekhar S P
19.30-20.15     Sponsored Session (INTAS)
  Chairperson   Sudeep Gupta
  Speaker   Amit Oza
  Moderator   Shona Nag
  Panelist  Ghanshyam Biswas,Somashekhar S P,Amit Agarwal,U D Bafna,Manisha Singh,Vamshi Krishna,Jatin Sarin
Scientific Program 15th July 2017,Saturday (Day 2)
Time Hall Topic
8.00-11.00 Hall 1  Lung Session- Director - Kumar Prabhash
Time Chairpersons  D. Behera,Rajesh Mistry,Rajeev Kumar Seam
8.00-8.07   Mohan Menon  Gefitinib (G) versus vinorelbine+cisplatin (VP) as adjuvant treatment in stage II-IIIA (N1-N2) non-small-cell lung cancer (NSCLC) with EGFRactivating mutation (ADJUVANT): A randomized, Phase III trial (CTONG 1104).
8.08-8.15  Manish Kumar  Randomized trial of cisplatin and etoposide in combination with veliparib or placebo for extensive stage small cell lung cancer: ECOGACRIN 2511 study.
8.16-8.23  Nilesh Lokeshwar  Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032.
     Panel Discussion
8.25-8.55  Moderator   Navneet Singh
  Panelist  P K Das,Senthil Rajjapa,Dinesh Singh,Gopal Sharma,Jay Mehta,Sayyed Junaid,Sushant Mittal
9.00-9.07  TVGS Tilak  Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial.
9.08-9.15  Prabhat Malik   Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024.
9.16-9.23  Koushik Chatterjee   Efficacy and safety results from AvaALL: An open-label, randomized phase III trial of standard of care (SOC) with or without continuous bevacizumab (Bev) treatment beyond progression (PD) in patients (pts) with advanced non-small cell lung cancer (NSCLC) progressing after first-line Bev and chemotherapy (chemo).
     Panel Discussion
9.25-9.55 Moderator  Nitesh Rohatgi
  Panelist  Muzammil Shaikh,Bivas Biswas,G K Jadhav,Rajender,Amanjit Bal,Jacob Sands,Pritesh Lohar,Linu Jacob,Vikas Goswami
10.00-10.07  Sushil Mandhaniya  Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial.
10.08-10.15  Jacob Sands  Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.
10.16-10.23   Saurabh Zanwar  Feasibility and outcome of repeat biopsy upon progression on tyrosine kinase inhibitors in patients with EGFR mutation positive adenocarcinoma of lung-an Indian tertiary cancer centre experience.
     Panel Discussion
10.25-10.55  Moderator   Amit Agarwal
  Panelist  B K Smruti,Vijay Anand Reddy,Bhavesh Parekh,Kumar Prabhash,Abhishek Mahajan,Ullas Batra,Sandeep Batra,Shubdha Kane,Amit Janu,Nalini Gupta
11.00-11.30     Tea Break
11.30-12.00     Sponsored Session(Astrazeneca Session)
  Chairpersons  D C Doval
  Senthil Rajappa  Management of NSCLC post progression to 1L EGFR TKI
  Moderator   Shyam Aggarwal
  Panelist  Ullas Batra,P.Suresh Nair,Kumar Prabhash,Rajesh Mistry,Boman Dhabhar,Sachin Hingmire
12.00-12.30    Sponsored Session(Pfizer Session)
  Chairpersons  D Behera,Kumar Prabhash
  Ullas Batra   Continuum of care in ALK rearranged NSCLC
  Panelist  Boman Dhabhar,Nikhil Gadyalpatil,Ghanashyam Biswas,Amit Joshi,Prasad Narayan
12.30-13.15    Sponsored Session(BI Session)
  Chairpersons  D C Doval
  T Raja  Time since start of first-line therapy as a predictive clinical marker for oral antiangiogenic agent in patients with previously treated NSCLC
     Panel Discussion - What is new in NSCLC? Integrating latest evidence into clinical practice.
  Moderator  Ullas Batra
  Panelist  Chetan Deshmukh,Chirag Desai,P.Suresh Nair,Kumar Prabhash,Manish Singhal,Nikhil Gadyalpatil,Shyam Aggarwal,Tvsvgk.Tilak, Manoj Prashar,Manish Kumar
     Lunch Break - 13.15-14.00
14.00-17.00  Hall 1   Breast Session- Director - Sachin Gupta
Time Chairpersons  Satish Jain,Hemant Malhotra,Vineet Talwar
14.00-14.07   Meenu Walia  APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC).
14.08-14.15  Gaurav Gupta  Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2.
14.16-14.23   Jaya Ghosh  Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC→4x doc vs. 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer.
     Panel Discussion
14.25-14.55  Moderator   Sudeep Gupta
  Panelist   Harit Chaturvedi,Ramesh Sarin,Chetan Deshmukh,Maheboob Basade,Manisha Singh,Sunandan Sharma,Tanuja Shet,Abhishek Mahajan
15.00-15.07  Peush Bajpai  Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2– advanced breast cancer (PALOMA-1; TRIO-18).
15.08-15.15  Rakesh Taran  MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy
15.16-15.23  Mandar Nadkarni   Mastectomy rates in relation to adoption of a margin guideline.
     Panel Discussion
15.25-15.55  Moderator   Shyam Aggarwal
  Panelist  Jyoti Bajpai,Shona Nag,Boman Dhabhar,Geeta Kadyapath,Lovenish Goyal,Sandeep Agarwal,Pradeep Garg,Komal Pruthy,Gurpreet Singh
16.00-16.07  Sachin Hingmire  Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.
16.08-16.15   Devrath Arya  OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).
16.16-16.23  Nita Nair  Yoga in women undergoing treatment for breast cancer: Impact on quality of life in a randomised controlled trial
     Panel Discussion
16.25-16.55 Moderator   Sandeep Goyle
  Panelist   Sandeep Jasuja,Seema Gulia,Devender Pal,Jacob George,Anish Maru,Ashutosh Gupta,Gaurav Agarwal,D S Sandhu,Prashant Parida
17.00-17.30     Sponsored Session(Pfizer Session)
  Chairpersons   Gurpreet Singh,Hemant Malhotra
  Shona Nag   Shifting Paradigms in the treatment of ER+ HER2- mBC : Role of Palbociclib
  Moderator  Shona Nag
  Panelist  Sandeep Jasuja,Ankur Bahl,Shyam Aggarwal,Jatin Sarin,Vamshi Krishna
17.30-18.00     Tea Break
18.00-18.45    Sponsored Session(BMS Lung Session)
  Chairpersons  D C Doval
  Bar Jair  Checkmate in NSCLC
  Moderator   Senthil Rajappa
  Panelist   Amit Agrawal,Nitesh Rohatgi,Ullas Batra,Chirag Desai,Mohan Menon,Sandeep Goyle
18.45-19.30    Sponsored Session(MSD Session)
  Chairperson  D C Doval
  Sanjiv Agarwala   Keytrends in Immuno-oncology.
  Moderator   Senthil Rajappa
  Panelist  Chirag Desai,T Raja,Nitesh Rohatgi,Manish Singhal,Ramesh Nimmagadda
19.30-20.30     Inauguration Function
8.00-10.00  Hall 2   Head & Neck Session- Director - Punita Lal
Time Chairpersons  B N Kapur,Ramesh Nimmagadda,K Kalaichelvi
8.00-8.07  Amit Joshi   Results of a phase II randomised controlled clinical trial comparing efficacy of cabazitaxel versus docetaxel as second line or above therapy in recurrent head and neck cancer
8.08-8.15  T P Sahoo   Phase III randomized trial of chemotherapy with or without bevacizumab (B) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Survival analysis of E1305, an ECOGACRIN Cancer Research Group trial.
8.16-8.23  Pritesh Lohar  A multicenter randomized controlled trial (RCT) of adjuvant chemotherapy (CT) in nasopharyngeal carcinoma (NPC) with residual plasma EBV DNA (EBV DNA) following primary radiotherapy (RT) or chemoradiation (CRT).
     Panel Discussion
8.25-8.55 Moderator   Pankaj Chaturvedi
  Panelist  Madhup Rastogi,Sandeep Agarwal,R Toprani,Pooja Pal,Sunny Jain,Chandrakant Pethe,S S Nirni,Manish Gupta
9.00-9.07  Sajjal Kakkar   The role of PET for predicting nodal response in locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) treated with chemoradiotherapy (CRT): Results of a prospective multicenter trial.
9.08-9.15  Prasad Narayan   Concurrent chemoradiotherapy with 3-weekly versus weekly cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: A phase 3 multicentre randomised controlled trial (ChiCTR-TRC-12001979)
9.16-9.23  Vijay Patil   Phase III randomized trial comparing weekly versus three-weekly (W3W) cisplatin in patients receiving chemoradiation for locally advanced head and neck cancer
     Panel Discussion
9.25-9.55 Moderator   Chirag Desai
  Panelist  A K Anand,Atul Sharma,Sapna Nangia,Richa Vaish,Maheboob Basade,Harit Chaturvedi,Sachin Hingmire,Tanveer Maksud
     Sponsored Session(Biocon Session)
10.00-10.15   Suresh VS Attili  Nimotuzumab as a single agent palliative therapy in performance score 3 and above in EGFR expressing tumors.(Accepted at ASCO 2017)Abstract No: e21635
10.15-10.30  Dilip Pawar  Twist Analysis of Open label Multi-centric study of BIOMAB –EGFR ( Nimotuzumab)in Head and Neck Cancer with Chemotherapy and /or Radiotherapy (Accepted at ASCO 2017) Abstract No: e17505
11.00-13.00  Hall 2  Pediatrics Session - Director - Sameer Bakhshi
Time Chairpersons   Sandeep Agarwala
11.00-11.07  Anirban Das  Temporal trends in chronic disease among survivors of childhood cancer diagnosed across three decades: A report from the Childhood Cancer Survivor Study (CCSS).
11.08-11.15  Sainath Bhethanabhotla   Age-associated vulnerability to treatment-related late cardiotoxicity: A report from the Childhood Cancer Survivor Study (CCSS).
     Panel Discussion - Can we normalize the life of childhood cancer survivors?
11.20-11.50  Moderator   Tushar Vora
  Panelist  Deepak Bansal, Ahit Biswas,Shruti Kakkar,Sonal Sharma,Richa Jain
11.55-12.10    Sameer Bakshi  Targeted and immunotherapy in ALL
12.10-12.25   Sandeep Agarwala  Evidence when not to do surgery in neuroblastoma Panel Discussion - Evidence for prophylactic drugs and vaccines during and post treatment of childhood cancer
12.25-12.55     Panel Discussion - Evidence for prophylactic drugs and vaccines during and post treatment of childhood cancer
  Moderator   Deepak Bansal
  Panelist  Sameer Bakhshi,Amita Mahajan,Atul Batra,Sainath Bhethanabhotla,Amita Trehan,Ruchira Mishra
Lunch Break - 12.45-14.00
14.00-14.30    Sponsored Breast Session (Novartis)
  Senthil Rajappa  CDK 4/6 inhibitors: Setting a new benchmark in Hormone Receptor positive advanced breast cancer
14.30-17.35  Hall 2  GU Session - Director - Sandeep Batra
  Chairperson   Rajeev Sood
14.30-14.37   Dipanjan Panda  Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT).
14.38-14.45  J S Sekhon  Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma (RCC): Validation of the 16-gene Recurrence Score in stage III patients.
     Panel Discussion
14.50-15.25  Moderator   Randeep Singh
  Panelist   Vimal Pandita,Sandeep Kaul,Anachal Agarwal,Bhavesh Parekh,P S Roy,Suhag,Debashish Choudhary,Narender Kumar
15.30-15.37   Amit Joshi  Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC).
15.38-15.45   Hemant Dadhich  Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab (pembro) in cisplatin ineligible advanced urothelial cancer (UC).
     Panel Discussion
15.50-16.25 Moderator   Kumar Prabhash
  Panelist  Meenu Gupta,Raman Kain,Ranjeet Sahoo,Jaskaran Singh,Rajat Saha,Ritesh Pruthy,Sandeep Kukkar,Prashant Penumade,Nalini Gupta,Sumit Jain
16.30-16.37  Amol Dongre  A randomized phase II cross-over study of abiraterone + prednisone (ABI) vs enzalutamide (ENZ) for patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC).
16.38-16.45  Kishore Kumar  Adding abiraterone for men with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Survival results from STAMPEDE (NCT00268476).
16.46-16.53  Alok Gupta  A phase IV, randomized, double-blind, placebo (PBO)-controlled study of continued enzalutamide (ENZA) post prostate-specific antigen (PSA) progression in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC).
16.54-17.01   Ganesh Bakshi  LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.
     Panel Discussion
17.05-17.35 Moderator   Govind Babu
  Panelist   P Suresh,Santosh Menon,Kumar Prabhash,Umang Mithal,Manish Pandey,Pawan Agrawal,Rakesh Boya Reddy,Amit Dhiman,Deepak Abrol
17.35-18.00     Sponsored Session(Pfizer Session)
  Chairperson  J S Sekhon,Anand Pathak
  Manish Singhal   Optimizing treatment in advanced metastatic renal cell carcinoma (mRCC)
  Moderator   Manish Singhal
  Panelist    Kishore Kumar,Manish Kumar,Manoj Parashar,Sachin Almel,Amit Joshi,Amit Dhiman,Vamshi Krishna,Rakesh Kapoor
15.00-16.30   Hall 3  Best Abstract Oral Presentation
  Session Coordinators   Prasad Narayanan,Vamshi Krishna,Pankaj Kumar,Gaurav Prakash
15.00-15.08    Best Abstract Oral Presentation
15.09-15.17    Best Abstract Oral Presentation
15.18-15.26    Best Abstract Oral Presentation
15.27-15.35    Best Abstract Oral Presentation
15.36-15.44    Best Abstract Oral Presentation
15.45-15.53    Best Abstract Oral Presentation
15.54-16.02    Best Abstract Oral Presentation
16.30-18.30  Hall 3  BST Session- Director - Jyoti Bajpai
Time Chairperson   Ramesh Nimmagadda
16.30-16.37  Sameer Rastogi  Discordance of histo-pathological diagnosis of patients with soft tissue sarcoma referred to tertiary care center
16.38-16.45   Ashish Gulia  Phase III study of aldoxorubicin vs investigators' choice as treatment for relapsed/refractory soft tissue sarcomas.
     Panel Discussion
16.50-17.20   Moderator  Sameer Bakshi
  Panelist   Shadab,Aanchal Agrawal,Shyam Aggarwal,Chadan Das,Rajat Gupta,Ashish Gulia,Munish Pruthy
17.25-17.32   Manoj Parashar  Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant unresectable or metastatic melanoma (MM).
17.33-17.40  Muzammil Shaikh  Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment.
17.41-17.48  Anubha Bharthuar    Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204
17.49-17.56   Indoo Ambulkar  A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC).
     Panel Discussion
18.00-18.30   Moderator  Jyoti Bajpai  
  Panelist  Bharat Rekhi,Boman Dhabar,B K Smruti,T Raja,Manish Agarwal,Archana Datta,Prakash Nayak
Scientific Program 16th July 2017, Sunday (Day 3)
Time Hall Topic
8.00-11.00  Hall 2  Hemato Lymphoid Session - Director - Pankaj Malhotra
Time Chairperson   Subhash Verma,Mehaboob Basade
8.00-8.07  Prantar Chakraborty   Phase 3 trial of momelotinib (MMB) vs ruxolitinib (RUX) in JAK inhibitor (JAKi) naive patients with myelofibrosis (MF).
8.08-8.15   Hari Menon  Bosutinib (BOS) versus imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): Initial results from the BFORE trial.
8.16-8.23   Deepesh Lad  A genetic risk-stratified, randomized phase 2 intergroup study of fludarabine/antibody combinations in symptomatic, untreated chronic lymphocytic leukemia (CLL): Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance).
     Panel Discussion
8.25-8.50  Moderator  Hemant Malhotra
  Panelist  Rajan Kapoor,Hasmukh Jain,Jasjeet Singh,Anita Tahlan,Neelam Verma,Anubha Bharthuar,Anuj Kumar Bansal
9.00-9.07  Sandip Shah  First-line treatment of iNHL or MCL patients with BR or R-CHOP/R-CVP: Results of the BRIGHT 5-year follow-up study.
9.08-9.15   Manju Sengar  Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: Results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL>60 study of the DSHNHL
9.16-9.23   Dinesh Bhurani  Autologous (auto) versus matched sibling donor (MSD) or matched unrelated donor (MUD) allogeneic (allo) hematopoietic cell transplantation (HCT) in follicular lymphoma (FL) patients (pts) with early chemoimmunotherapy failure (ECF): A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis.
     Panel Discussion
9.25-9.50  Moderator   Reena Nair
  Panelist   Boman Dhabhar,Atul Sharma ,Dharma R Choudhary,Ankur Bahl,Tanuja Shet,Chetan Deshmukh,Shriram Kane, Gagan Saini
10.00-10.07   Gaurav Prakash  Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): An open-label, phase 1b study
10.08-10.15   Rahul Naithani  Carfilzomib-lenalidomide-dexamethasone (KRd) vs carfilzomib-cyclophosphamide-dexamethasone (KCd) induction: Planned interim analysis of the randomized FORTE trial in newly diagnosed multiple myeloma (NDMM).
10.16-10.23  Joseph John  Impact of denosumab (DMB) compared with zoledronic acid (ZA) on renal function in the treatment of myeloma bone disease.
     Panel Discussion
10.25-10.50  Moderator   Pankaj Malhotra
  Panelist  Rahul Bhargava,Ryaz Ahmed,Anirudh,Avinash Pophali,Sharat Damodar,Kaanwardeep Kwatra,Sachin Gupta,Chepsy,Uday,Adwaita Gore,Ajay Sharma,Saurabh Bhattacharya
8.00-11.00  Hall 1   Molecular Oncology Session - Director - D C Doval,Purvish Parikh,Shailesh Bondarde
8.00-8.10  Govind Babu  Liquid biopsy vs tissue biopsy (Indian data)
8.10-8.20 Suresh Babu  Liquid biopsy vs tissue biopsy (Indian data)
8.20-8.40 Prashant Mehta  NGS raw data and Bioinformatics 
8.40-9.20    Indian Data in Molecular Oncology
  Moderator   Randeep Singh
   Vinayak Maka   TBD
     TBD
   Anita Ramesh   TBD
     Panel Discussion-Molecular Oncology Tumor Board - SOP and Logistics
9.20-9.35   Moderator  Purvish Parikh
  Panelist  Amit Verma,Dinesh Doval,Chirag Desai,Shailesh Bondadre,Shyam Aggarwal,Sunil Agrawala
9.35-9.55  Anurag Mehta  Rebiopsy/ T719M mutation testing
     Panel discussion - Practical collaborative work
9.55-10.15  Moderator   Shyam Aggarwal
  Panelist   G S Bhattacharaya,Anish Maru,Sachin Hingmire,Dinesh Doval,Bharat Bhosle,Neeraj Jain
10.15-10.45  Sanjiv Agarwala   Practical aspects for clinical management of Immuno-oncology
  Moderator  Chirag Desai
  Panelist  Randeep Singh,Manish Singhal
10.45-11.00  Manish Singhal   Take home message
11.00-12.00  Hall 1 Validectory Function